Long-term outcome of Quetiapine use for psychosis among Parkinsonian patients

Movement Disorders

Volumn 18, Issue 5, 2003, Pages 510-514

  Fernandez, Hubert H ^a   Trieschmann, Martha E ^a   Burke, Monica A ^a   Jacques, Carol ^a   Friedman, Joseph H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Dementia; Drug induced psychosis; Long term; Parkinson's disease; Quetiapine

Indexed keywords

CLOZAPINE; LEVODOPA; OLANZAPINE; QUETIAPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DELUSION; DEMENTIA; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DRUG TOLERANCE; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0038485957     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10374     Document Type: Article

References (39)

1. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
2. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
3. Carter JH, Stewart BJ, Archnold PG, Parkinson Study Group. Living with a person who has Parkinson's disease: the spouse's perspective by stage of the disease. Mov Disord 1998;33:20-28.
4. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease. In: Weiner WJ, Lang AE, editors. Drug-induced psychiatric states. Behavioral neurology of movement disorders, advances in neurology. Vol. 65, New York: Raven Press Ltd.; 1995. p 115-138.
5. Celesia GC, Barr AN. Psychosis and psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200.
6. Cotzias GC, Papavasilou PS, Ginos J, Steck A, Duby S. Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annu Rev Med 1971;22:305-326.
7. Goodwin FK. Psychiatric side effects of levodopa in men. JAMA 1971;218:1915-1921.
8. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970;2:177-180.
9. Mindham RHS. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33:188-191.
10. Dewey RB, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000;55:1753-1754.
11. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community based study. Arch Neurol 1999;56:595-601.
12. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996;53:1265-1268.
13. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
14. Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's Disease. N Engl J Med 1999;340:757-763.
15. The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999;353:2041-2042.
16. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
17. Arndt J, Skarsfeld T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsy-chopharmacology 1998;18:63-101.
18. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219.
19. Juncos JL, Evatt ML, Jewart D. Long-term effect of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998;50:A70-71.
20. Juncos JL, Arvanitis L, Sweitzer D, et al. Quetiapine improves psychotic symptoms associated with Parkinson's disease. Neurol 1999;52(Suppl. 2):A262.
21. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 2000;15:579-581.
22. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
23. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-144.
24. Factor SA, Reddy S, Molho ES, Feustel PJ. The effect of Quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.
25. Weiner WJ, Minagar A, Shulman LM. Quetiapine for L-dopa induced psychosis in PD. Neurology 2000;54:1538.
26. Fernandez HH. Quetiapine for L-dopa-induced psychosis in PD. Neurology 2000;55:899.
27. Samanta J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson's disease. Mov Disord 1998;13(Suppl.): 274.
28. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth ed. Washington DC: American Psychiatric Association; 1994.
30. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46: 922-930.
31. McKeith IG, Fairbairn AF, Bothwell RA, Moore PB, Ferrier LN, Thompson P, Perry RH. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994;44:872-877.
32. Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292.
33. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997;54: 549-557.
34. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.
35. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patient with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
36. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994;344:681.
37. Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50:1195-1196.
38. Friedman JH, Goldstein SM, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot trial. Clin Neuropharmacol 1998;21: 285-288.
39. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999;14:1014-1016.